Wall Street Analysts Predict a 72.22% Upside in Faeth Therapeutics, Inc. (FTH): Here's What You Should Know
The mean of analysts' price targets for Faeth Therapeutics, Inc. (FTH) points to a 72.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks
Faeth Therapeutics Announces FDA Grant of Fast Track Designation for PIKTOR Plus Paclitaxel in Biomarker-Selected Advanced Endometrial Cancer
Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the combination of sapanisertib and...
Business Wire
Faeth Therapeutics Strengthens Executive Team with Senior Leadership Appointments
Faeth Therapeutics, Inc. (Nasdaq: FTH) today announced the appointments of Deepak Tiwari as Senior Vice President, Technical Operations, and Matt Biegler as Senior Vice President, Investor Relations, as the company prepares for upcoming PIKTOR clinical milestones. Tiwari will lead Faeths technical...
Business Wire
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Faeth Therapeutics, Inc. (Nasdaq: FTH) today announced that the Compensation Committee of Faeths Board of Directors granted two new employees options to purchase an aggregate of 11,000 shares of the Companys common stock in connection with their employment (collectively, the Option Awards). The...
Business Wire
Faeth Therapeutics to Present PK/PD Modeling That Informed PIKTOR Dose Selection in Ongoing FTH-PIK-201 Trial at Upcoming Scientific Conference
Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing PIKTOR, an investigational all-oral, multi-node inhibitor of the PI3K/AKT/mTOR pathway, will present translational data and pharmacokinetic/pharmacodynamic (PK/PD) analysis for PIKTOR, its oral combination of serabelisib...
Business Wire
Faeth Therapeutics Reports Second Quarter 2026 Financial Results and Operational Updates
Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing PIKTOR, an investigational all-oral, multi-node inhibitor of the PI3K/AKT/mTOR pathway, today announced financial results for the quarter ended June 30, 2026, and highlighted recent corporate accomplishments and 2026...
Business Wire
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Faeth Therapeutics, Inc. (Nasdaq: FTH) today announced that the Compensation Committee of Faeths Board of Directors granted two new employees options to purchase an aggregate of 25,500 shares of the Companys common stock in connection with their employment (collectively, the Option Awards). The...
Business Wire
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Faeth Therapeutics, Inc. (Nasdaq: FTH) today announced that the Compensation Committee of Faeths Board of Directors granted six new employees options to purchase an aggregate of 180,350 shares of the Companys common stock in connection with their employment (collectively, the Option Awards). The...
Business Wire
Sensei Biotherapeutics Announces Name Change to Faeth Therapeutics, Focused on Advancing PIKTOR, an Oral Therapy Targeting One of the Most Frequently Altered Pathways in Cancer
Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that it has changed its corporate name to Faeth Therapeutics, Inc. (the Company). The Companys common stock is expected to begin trading on the Nasdaq Capital Market under the new ticker symbol FTH on June 16, 2026, and the Company has...
Business Wire